Factors Associated with Unfavourable Treatment Outcomes in Patients with Tuberculosis: A 16-Year Cohort Study (2005-2020), Republic of Karakalpakstan, Uzbekistan.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
05 12 2021
Historique:
received: 30 08 2021
revised: 09 11 2021
accepted: 13 11 2021
entrez: 10 12 2021
pubmed: 11 12 2021
medline: 15 12 2021
Statut: epublish

Résumé

Tuberculosis (TB) remains a public health burden in the Republic of Karakalpakstan, Uzbekistan. This region-wide retrospective cohort study reports the treatment outcomes of patients registered in the TB electronic register and treated with first-line drugs in the TB Programme of the Republic of Karakalpakstan from 2005-2020 and factors associated with unfavourable outcomes. Among 35,122 registered patients, 24,394 (69%) patients were adults, 2339 (7%) were children, 18,032 (51%) were male and 19,774 (68%) lived in rural areas. Of these patients, 29,130 (83%) had pulmonary TB and 7497 (>22%) had been previously treated. There were 7440 (21%) patients who had unfavourable treatment outcomes. Factors associated with unfavourable treatment outcomes included: increasing age, living in certain parts of the republic, disability, pensioner status, unemployment, being HIV-positive, having pulmonary TB, and receiving category II treatment. Factors associated with death included: being adult and elderly, living in certain parts of the republic, having a disability, pensioner status, being HIV-positive, and receiving category II treatment. Factors associated with failure included: being adolescent, female, having pulmonary TB. Factors associated with loss to follow-up included: being male, disability, pensioner status, unemployment, receiving category II treatment. In summary, there are sub-groups of patients who need special attention in order to decrease unfavourable treatment outcomes.

Identifiants

pubmed: 34886554
pii: ijerph182312827
doi: 10.3390/ijerph182312827
pmc: PMC8657882
pii:
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Références

Int J Environ Res Public Health. 2021 Apr 13;18(8):
pubmed: 33924701
Clin Microbiol Infect. 2020 Feb;26(2):180-188
pubmed: 31336202
Med Sci Monit. 2014 Nov 02;20:2125-31
pubmed: 25362504
PLoS One. 2015 Jun 15;10(6):e0128907
pubmed: 26075615
Int J Tuberc Lung Dis. 2002 Oct;6(10):879-86
pubmed: 12365574
J Virus Erad. 2019 Nov 04;5(4):225-230
pubmed: 31754446
Biomed Res Int. 2017;2017:3974651
pubmed: 29445736
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25
pubmed: 29149917
BMC Public Health. 2019 Jul 22;19(1):973
pubmed: 31331311
Int J Environ Res Public Health. 2021 Apr 27;18(9):
pubmed: 33925705
Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94
pubmed: 25216832
Int J Tuberc Lung Dis. 2004 May;8(5):598-602
pubmed: 15137537
Pneumonol Alergol Pol. 2012;80(6):533-40
pubmed: 23109205
Health Syst Transit. 2014;16(5):1-137, xiii
pubmed: 25689490
PLoS One. 2011;6(11):e27610
pubmed: 22110689
BMC Infect Dis. 2019 Aug 16;19(1):723
pubmed: 31420021
Environ Health Perspect. 2001 Jun;109(6):547-9
pubmed: 11445505
J Clin Microbiol. 2019 Jun 25;57(7):
pubmed: 31043465
Trop Med Int Health. 2009 Nov;14(11):1338-46
pubmed: 19735372
Int J Environ Res Public Health. 2021 Apr 28;18(9):
pubmed: 33924862
Medicina (B Aires). 2017;77(4):267-273
pubmed: 28825568
Med Klin (Munich). 2009 Oct 15;104(10):772-9
pubmed: 19856151
Medicine (Baltimore). 2019 Jun;98(26):e16071
pubmed: 31261516
Int J Environ Res Public Health. 2021 Apr 12;18(8):
pubmed: 33921547
Eur Respir J. 2013 Mar;41(3):635-43
pubmed: 22790913
Med Tr Prom Ekol. 2014;(8):1-4
pubmed: 25549450
Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1127-1134
pubmed: 30236179
BMJ Open. 2018 Sep 25;8(9):e022111
pubmed: 30257846
Euro Surveill. 2013 Oct 17;18(42):
pubmed: 24176581
Int J Environ Res Public Health. 2021 Apr 27;18(9):
pubmed: 33925377
BMC Infect Dis. 2017 Jun 24;17(1):449
pubmed: 28646854

Auteurs

Jamshid Gadoev (J)

WHO Country Office in Uzbekistan, 16-Tarobiy, Tashkent 100100, Uzbekistan.

Damin Asadov (D)

Center of Development of Professional Qualification of Medical Personnel, Tashkent 100007, Uzbekistan.

Anthony D Harries (AD)

Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, 2 Rue Jean Lantier, 75001 Paris, France.
Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.

Ajay M V Kumar (AMV)

Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, 2 Rue Jean Lantier, 75001 Paris, France.
International Union Against Tuberculosis and Lung Disease, South-East Asia Office, C-6, Qutub Institutional Area, New Delhi 110016, India.
Yenepoya Medical College, Yenepoya (Deemed to be University), Mangaluru 575018, India.

Martin Johan Boeree (MJ)

Department of Lung Diseases, Radboudumc, 6500 HB Nijmegen/TB Expert Centre Dekkerswald, 6561KE Groesbeek, The Netherlands.

Araksya Hovhannesyan (A)

World Health Organization Regional Office for Europe, UN City, Marmorvej 51, DK-2100 Copenhagen, Denmark.

Lianne Kuppens (L)

WHO Country Office in Uzbekistan, 16-Tarobiy, Tashkent 100100, Uzbekistan.

Askar Yedilbayev (A)

World Health Organization Regional Office for Europe, UN City, Marmorvej 51, DK-2100 Copenhagen, Denmark.

Oleksandr Korotych (O)

World Health Organization Regional Office for Europe, UN City, Marmorvej 51, DK-2100 Copenhagen, Denmark.

Atadjan Hamraev (A)

Center of Development of Professional Qualification of Medical Personnel, Tashkent 100007, Uzbekistan.

Kallibek Kudaybergenov (K)

Republican Phthisiology and Pulmonology Center Named after Sultanov, Nukus 1735401, Republic of Karakalpakstan.

Barno Abdusamatova (B)

Ministry of Health of Republic of Uzbekistan, Tashkent 100011, Uzbekistan.

Bakhtinur Khudanov (B)

Ministry of Health of Republic of Uzbekistan, Tashkent 100011, Uzbekistan.

Masoud Dara (M)

World Health Organization Regional Office for Europe, UN City, Marmorvej 51, DK-2100 Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH